NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).. As CMO, Dr. Gandhi will oversee the clinical development of NextPoint's precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. Cambridge, MA / Leverkusen, Germany January 10, 2023 NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. being referred to as relevant persons). Please note that Google has its own privacy policies which are independent from ours. Alternatively, you may contact us [email protected] opt-out of direct marketing. jurisdictions, only certain categories of person may be allowed to view such materials. 10+ years of pharmaceutical or biotechnology industry experience or mix of industry and academic experience in oncology or cancer immunotherapy with an emphasis on translational research, clinical biomarkers, and monoclonal antibodies, Proven track record of transitioning biomarkers from the bench to the clinic, Strong knowledge of immuno-oncology and associated biomarker approaches, Technical expertise in IHC, RNAscope, flow cytometry, genetics (including ctDNA), RNA-Seq, NanoString, qPCR and ELISAs, Proven success with filing INDs and supporting clinical trials, Competency with bioinformatic datasets and experience collaborating with bioinformaticians to analyze publicly available datasets, Excellent communication and interpersonal skills, personal integrity, professional manner, and ability to gain respect and develop good working relationships with cross functional personnel at all levels, Ability to balance multiple stakeholders and projects simultaneously, and able to operate with high accountability and under tight deadlines, Forward looking thinker, who actively seeks opportunities and proposes solutions with strong decision-making capability, A collaborator who communicates in an open, clear, complete, timely and consistent manner who listens effectively and invites response and discussion, Direct and run clinical operations and clinical trial launch activities for clinical programs, Manage clinical research organizations, clinical and testing lab vendors, Establish clinical operations infrastructure across the organization, Maintain relationships with Sites and KOLs, Represent NextPoint at Scientific and Investigator Meetings, Stay apprised of current trends in clinical trials research and regulatory landscape, Take responsibility for launch and day-to-day operational management of clinical trials including study sites, Participate in Clinical Vendor Governance and Safety Review Committee Meetings, Design and perform ligand binding assays in multi-well formats to analyze novel antibody therapeutics, Develop and execute functional assays involving primary human immune cells, mammalian cell culture, and multi-color flow cytometry to screen novel antibody therapeutics in an immune-oncology setting, Work independently to design and conduct experiments, analyze, interpret, and communicate data in team meetings and to leadership, Support the laboratory organization and operations by maintaining lab equipment and managing reagent and supply inventories, Bachelors degree in cell/molecular biology, immunology, or cancer biology or equivalent field, 2 + years hands-on experience in drug discovery research preferably in an industry setting, Experience with cell-based functional immune assays such as MLR, immune cell activity assays, and cytokine release assays, Experience with multiparameter flow cytometry, Hands on experience with murine tumor models preferred, Excellent verbal and written communication skills with a demonstrated ability to work collaboratively and thrive in a team environment, Excellent interpersonal skills and willingness to learn a variety of new techniques and technologies; flexibility to adapt to rapidly changing priorities and deadlines. Cancer Immunol Res. & LEVERKUSEN, Germany-(BUSINESS WIRE)-NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. the securities prospectus. CAMBRIDGE, Mass. Among these areas are oncology, immunology, rare diseases, vaccines, potential cures in other core areas of Sanofis business footprint, and digital health solutions. Japan or in any other jurisdiction in which such offer or solicitation is not authorized or to any investment decision regarding the securities referred to herein should only be made on the basis a Glance, Latest In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. 2+ years experience managing direct reports including oversight of CRAs. requirements under the U.S. Securities Act or to, or for the benefit of, U.S. persons. & Rewards, Values restricted. Copyright 2022 NextPoint Therapeutics, Inc. All Rights Reserved. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the . News, Conditions of jurisdiction. Cookies, as well as other tracking technologies, such as HTML5 local storage, and Local Shared Objects (such as Flash cookies), and similar mechanisms, may record information such as a unique identifier, information you enter in a form, IP address, and other categories of data. Our Site may contain links or otherwise provide access to another website, mobile application, or Internet location (collectively Third-Party Sites). With our distinctive knowledge of people, animals and plants, we focus on the areas of health care and nutrition. The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. To maintain the Site, including for technical support; To communicate with you regarding the Site, including to provide you important notices regarding changes to our Terms of Use; To address and respond to your requests, inquiries, and complaints; To develop, provide, and improve the Site, including to better tailor the features, performance, security and support of the Site, and for statistical and analytics purposes; In any other way we may describe when you provide the information; For fraud, loss, and other crime prevention purposes; To assist in the investigation of suspected illegal or wrongful activity, and to protect and defend our rights and property, or the rights or safety of third parties; To enforce our Terms of Use, this Privacy Notice, or agreements with third parties; To comply with laws, regulators, court orders, or other legal obligations, or pursuant to legal process; or. We encourage you to read the privacy policies of any Third-Party Site with which you choose to interact. We thank Dr. Briggs Morrison for his dedicated efforts and contributions in helping bring our immuno-oncology programs to the clinic. To learn more, visit, Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. application, Your INFORMATION FROM CHILDREN UNDER 13 YEARS OF AGE. Alternatively, users can deactivate cookies from third-party providers by going to the network advertising initiatives deactivation page (link:https://optout.networkadvertising.org/?c=1). +49 30 468 1111, Alfred-Nobel-Str. The tender offer referenced herein is not being made, directly or indirectly, in or into the United Demand, Breakthroughs Professional skill highlights: lab facility planning and fit out, lab operations management, project management, document management (QMS), budgeting, procurement, safety program management and technical training. We have no control over, do not review, and are not responsible for Third-Party Sites, their content, or any goods or services available through the Third-Party Sites. Existing investors that took part in the financing include MPM Capital Management, Dana-Farber Cancer Institutes Binney Street Capital and NextPoint founder Gordon Freeman, PhD. 2015 May 15;21(10):2359-66. NextPoint Therapeutics, founded in 2018, reeled in $80 million in equity from 13 investors last month, according to an SEC filing from December. KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target. Related Persons. Stewardship, Pharmaceuticals Freemans and Zangs independent discovery and characterization of the HHLA2 pathway formed the basis of the NextPoint approach. You are not required to provide all Personal Data identified in this Privacy Notice in order to use the Site; however, if you do not provide the Personal Data requested, we may be unable to provide some or all of the Site to you. Please note, however, we cannot fully eliminate security risks associated with the storage and transmission of Personal Data. Safety, Climate Information, Recognizing Statements, Reports Management, Code of Conduct Higher wind gusts possible.. The investment portfolio includes more than 50 companies. The company assumes no liability whatsoever to update these forward-looking statements or to conform, Deutsch In other jurisdictions, only certain categories of person may be allowed to view such In relation to each member state of the European Economic Area which has implemented the Directive NextPoint is developing medications targeting this novel axis to expand the benefit of immunotherapies to more cancer patients. While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments,. Please note that, subject to applicable law, we may continue to process your Personal Data even where you object if there are compelling legitimate grounds for processing that override your interests and rights, or where processing is necessary to establish, exercise, or defend legal claims. Bayers leadership in agriculture provides tailored solutions for farmers to plant, grow and protect their harvests using less land, water and energy. The purpose of cookies is to remember the browser over time and distinguish one browser instance (or user) from all others. Fraudulent Brands, Commitment to I am currently pursuing a M.Sc. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. NextPoint Therapeutics by MPM, Binney Street Capital, and Simcere Pharmaceutical Acquisition by DermBiont of SeylanMed's lead drug candidate, a topical AKT inhibitor gel Formation and equity financing of Dianthus Therapeutics by 5AM Ventures, Fidelity Management & Research Company, Venrock Healthcare Capital Partners, Fairmount Subject to applicable contractual or legal restrictions, in connection with a contemplated reorganization or an actual reorganization of our business, in connection with financing, a sale or other transaction involving the disposal of all or part of our business or assets, including for the purpose of permitting the due diligence required to decide whether to proceed with a transaction. Monsanto, How to We encourage you to review this Privacy Notice often to stay informed of how we may process your information. The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. NextPoint is building a deep understanding of the HHLA2 tumor-specific immune-escape mechanism, with the ultimate goal of establishing standalone treatments in cancers with high HHLA2 expression, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. Community, Bayer Science, Business About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. We do not accept any responsibility or liability for these policies and procedures. Consulting, Our Bayer Global in the United States, Australia, Canada, South Africa or Japan or any other jurisdiction, where As permitted by law, certain data elements may not be subject to access, modification, portability, restriction, and/or deletion. available on the website of the Luxembourg Stock Exchange (www.bourse.lu). NextPoint Therapeutics has announced an $80 million Series B funding round to move two lead precision immuno-oncology programs into the clinic. Our team of . This Privacy Notice is intended to describe how NextPoint Therapeutics, Inc., (NextPoint) collects, uses, and shares Personal Data that you submit to us and that we collect through our websitehttps://www.nextpointtx.com(the Site). Janakiram M, Chinai JM, Fineberg S, et al. securities in any Relevant Member State means the communication in any form and by any means of Stockholders' Meeting, Notice The final prospectus, when published, will be NextPoints programs aim to deliver monotherapies for cancer patients without viable treatment options. and Follow-up Questions, How to NextPoint originated from the combined expertise of its academic founders, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute, and XingXing Zang, PhD, of Albert Einstein College of Medicine. Nutrition Any person who wishes to view these materials must first satisfy themselves that they are NextPoints approach re-activates immune cells in tumors that are suppressed by HHLA2-driven immune evasion. Committed to developing novel immunotherapies. +49 214 30 1, Mllerstrae 178 In addition, you may contact the relevant data protection authority in the EU Member State of your residence, place of work or of the alleged infringement. By using any portion of the Site, you acknowledge and consent to the transfer of your information to our facilities in the United States. Transmit materials that contain any viruses, Trojan horses, worms, time bombs, cancelbots or other computer-programming routines that are intended to damage, detrimentally interfere with, surreptitiously intercept or expropriate any system, data or personal information. One of the candidates, lademirsen, is in a phase 2 trial for the treatment of Alport Syndrome. Sports, Promotion on for In most cases, we need to process certain components of your Personal Data in order to fulfill our contractual obligations to you and for our legitimate interests. archive, Shareholder The most recent version of the Privacy Notice is reflected by the version date located at the top of this Privacy Notice. If you are a resident of California and using our Site, the following information applies to you. Further, it does solutions A browser sends cookies to a server when the browser makes a connection to the server (for example, when requesting a web page from the same domain that created the cookie).
Christian Hull Brothers, Westover High School Football Roster, Post Tribune Obituaries, Articles N